Tempest To Present At The H.C. Wainwright 26Th Annual Global Investment Conference
(MENAFN- GlobeNewsWire - Nasdaq) BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest, will present at the H.C. Wainwright 26th Annual Global investment Conference.
The company presentation will be available for on-demand viewing Monday, September 9, 2024, at 7:00 a.m. ET on the investor section of the Tempest website at .
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at .
Investor & Media Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
...
Aljanae Reynolds
Wheelhouse Life Science Advisors
...
-----------------
i If approved by the FDA
MENAFN05092024004107003653ID1108640128
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.